BIOVECTRA is celebrating the completion of a more than $90-million biologics expansion at the company’s new state-of-the-art Biomanufacturing Centre in Charlottetown. The expansion was announced by BIOVECTRA, together with the federal and provincial governments, in November of 2021. BIOVECTRA’s CEO says the expansion places BIOVECTRA at the forefront of supporting the next generation of treatments for today’s rare and incurable diseases and producing vaccines to tackle future pandemics. The expansion was part of a national effort to expand domestic capabilities to manufacture mRNA vaccines and therapeutics.
